Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2009

Merck & Co. Acquires Rights to C. Difficile Drugs from Medarex and MBL for $60M

Merck & Co. Acquires Rights to <i>C. Difficile</i> Drugs from Medarex and MBL for $60M

Merck & Co. to pay $60 upfront for C.Difficile treatment

  • Medarex and Massachusetts Biologic Laboratories (MBL) have out-licensed to Merck & Co. an antibody combination that targets C. difficile in a deal worth over $225 million. Merck gains the worldwide rights to market and further develop the CDA-1 and CDB-1 antibody combination and will pay Medarex and MBL $60 million up front.

    A further $165 million will be paid upon the completion of certain milestones. Medarex and MBL will recieve double-digit royalties and milestones if certain sales levels are met. Pursuant to a prior co-development agreement, Medarex and MBL will divide all payments equally.

    A Phase II multicenter, randomized, double-blind trial showed a reduction in the incidence of infection among 200 patients when compared to those taking a placebo, says Merck. An oral presentation of the results is slated for June 2 at Digestive Disease Week.ADNFCR-2184-ID-19131120-ADNFCR



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »